Emerging markets remain a vital growth engine for Boston Scientific Corporation BSX, anchoring the company’s broader international strategy and long-term expansion plans. In the first quarter of 2025, ...

Boston Scientific is flexing its financial muscles with a strong 16.6% year-to-date gain, easily outpacing the 5.6% return of ...

Shares of Boston Scientific Corp. BSX slid 1.03% to $103.10 Tuesday, on what proved to be an all-around positive trading ...

With a market cap of $155.7 billion, Boston Scientific Corporation (BSX) is a global medical device company operating through ...

Boston Scientific has a better P/E ratio of 76.28 than the aggregate P/E ratio of 53.33 of the Health Care Equipment & Supplies industry. Ideally, one might believe that Boston Scientific Inc. might ...

Boston Scientific leads in MedSurg and Cardiovascular with strong Q1 growth, solid margins, and smart acquisitions. Find out ...

The headline numbers for Elastic (ESTC) give insight into how the company performed in the quarter ended April 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Boston Scientific has pulled global sales of, and is no longer seeking FDA approval for, its Acurate neo2 and Acurate Prime aortic valve systems. In a May 28 Securities and Exchange Commission filing, ...

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.